Cancidas (Caspofungin)

What Is Cancidas and What Is It Used For?

Cancidas (caspofungin) is an antifungal medication belonging to the echinocandin class. It is administered by intravenous infusion and is used to treat serious invasive fungal infections caused by Candida and Aspergillus species in children, adolescents, and adults.

Cancidas contains the active ingredient caspofungin, which belongs to a group of medicines called echinocandins. Echinocandins represent one of the most important classes of antifungal drugs developed in recent decades, and they have become a cornerstone of treatment for many life-threatening fungal infections. Unlike older antifungal agents such as azoles and amphotericin B, echinocandins target a unique component of the fungal cell wall, giving them a distinct mechanism of action and a generally favorable safety profile.

Invasive fungal infections are a significant cause of morbidity and mortality worldwide, particularly among patients who are immunocompromised, critically ill, or recovering from major surgery. According to the World Health Organization (WHO), invasive fungal diseases affect more than 6.5 million people globally each year and are responsible for approximately 3.8 million deaths annually. Candida and Aspergillus species are among the most commonly implicated organisms in these serious infections.

Approved Indications

Cancidas is approved for the treatment of the following conditions:

• Invasive candidiasis: Serious fungal infections of tissues or organs caused by Candida yeast species. This includes candidemia (Candida in the bloodstream), intra-abdominal abscesses, peritonitis, and pleural space infections. Patients at risk include those who have recently undergone surgery, those in intensive care units, and those with weakened immune systems. Fever and chills that do not respond to antibiotic treatment are among the most common symptoms of invasive candidiasis.
• Invasive aspergillosis (salvage therapy): Cancidas is used to treat invasive aspergillosis when other antifungal treatments such as amphotericin B or voriconazole have not been effective or have caused intolerable side effects. Aspergillosis is caused by the mold Aspergillus and most commonly affects the lungs, sinuses, and brain. Patients at highest risk include those receiving chemotherapy, organ transplant recipients, and individuals with severely weakened immune systems.
• Empirical antifungal therapy: Cancidas is used to treat suspected fungal infections in patients with fever and a low white blood cell count (febrile neutropenia) that does not improve with antibiotic treatment. This approach is critical because fungal infections in neutropenic patients can progress rapidly and are difficult to diagnose early.

How Cancidas Works

Caspofungin works by inhibiting the enzyme beta-(1,3)-D-glucan synthase, which is responsible for producing beta-(1,3)-D-glucan, an essential structural polysaccharide in the cell walls of many pathogenic fungi, including Candida and Aspergillus species. Beta-glucan provides mechanical strength and rigidity to the fungal cell wall, much like the steel framework of a building. When this component is missing, the fungal cell wall becomes structurally compromised, leading to osmotic instability and ultimately cell death.

Importantly, human cells do not contain beta-(1,3)-D-glucan and do not produce it, which is why caspofungin can selectively target fungal cells without significant toxicity to the patient's own cells. This selective mechanism of action contributes to the generally favorable safety profile of echinocandin antifungals compared to some older antifungal agents.

Against Candida species, caspofungin exhibits fungicidal activity, meaning it directly kills the fungal cells. Against Aspergillus species, caspofungin demonstrates fungistatic activity at the actively growing tips of the fungal hyphae, preventing further growth and allowing the patient's immune system to clear the infection. Clinical studies have confirmed that caspofungin achieves clinically meaningful drug concentrations in most body tissues and fluids relevant to invasive fungal infections.

What Should You Know Before Taking Cancidas?

Before receiving Cancidas, your doctor should be informed about any drug allergies, liver problems, current medications (especially cyclosporine), and pregnancy or breastfeeding status. Cancidas should not be given to patients who are allergic to caspofungin or any of its excipients.

Cancidas is a powerful antifungal medication used in serious clinical situations. As with any medicine, it is essential that your healthcare team has a complete picture of your medical history, current medications, and overall health before starting treatment. This information helps ensure that Cancidas is safe and appropriate for you and allows your doctor to anticipate and manage any potential complications.

Contraindications

You must not receive Cancidas if:

• You are allergic (hypersensitive) to caspofungin or any of the other ingredients in this medicine, including sucrose, mannitol (E421), glacial acetic acid, and sodium hydroxide

If you are unsure whether you have any allergies to these substances, consult your doctor, nurse, or pharmacist before receiving the medication. True allergy to caspofungin is very rare, but it is important to report any history of allergic reactions to medications.

Warnings and Precautions

Talk to your doctor, nurse, or pharmacist before receiving Cancidas if any of the following apply to you:

• Allergy to other medications: Inform your doctor of any known drug allergies, as cross-sensitivity between different medications is possible, although uncommon with echinocandins
• Liver problems: If you have ever had hepatic impairment or liver disease, you may require a reduced dose of Cancidas. Patients with moderate hepatic insufficiency (Child-Pugh score B) typically receive a lower maintenance dose of 35 mg daily after the initial loading dose. Caspofungin is not recommended in patients with severe hepatic impairment (Child-Pugh score C) due to insufficient clinical data
• Cyclosporine use: If you are currently taking cyclosporine (used to prevent organ transplant rejection or to suppress the immune system), your doctor may need to perform additional blood tests to monitor your liver function during treatment, as concomitant use may increase the risk of elevated liver enzymes
• Other medical conditions: Report any other significant health conditions to your healthcare team, as they may affect the safety or dosing of Cancidas

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving this medicine. The safety of Cancidas during pregnancy has not been established in clinical trials. It should only be used during pregnancy if the potential benefit to the mother clearly outweighs the potential risk to the developing baby. Your doctor will carefully weigh these considerations.

Women who are receiving Cancidas should not breastfeed. It is not known whether caspofungin is excreted in human breast milk. If treatment with Cancidas is necessary, discuss appropriate alternatives for infant feeding with your healthcare provider.

Driving and Operating Machinery

There is no evidence suggesting that Cancidas affects your ability to drive or operate machinery. However, if you are hospitalized for the treatment of a serious fungal infection, your overall medical condition and any other medications you are receiving may affect your alertness and coordination. Follow your doctor's advice regarding these activities.

Sodium Content

Cancidas contains less than 1 mmol (23 mg) of sodium per vial, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.

How Does Cancidas Interact with Other Drugs?

Cancidas has clinically significant interactions with cyclosporine (increased liver enzyme risk), tacrolimus (reduced tacrolimus levels), and several enzyme inducers including rifampicin, efavirenz, nevirapine, phenytoin, carbamazepine, and dexamethasone, which may reduce caspofungin blood levels and require dose adjustments.

Tell your doctor, nurse, or pharmacist if you are taking, have recently taken, or might take any other medicines, including over-the-counter medicines and herbal remedies. This is important because Cancidas can affect the way some other medicines work, and other medicines can also affect the way Cancidas works. Understanding these interactions is essential for safe and effective treatment.

Major Interactions

Additional Interaction Considerations

Caspofungin is not a substrate of cytochrome P450 enzymes and does not inhibit or induce major CYP isoenzymes. It is primarily metabolized through hydrolysis and N-acetylation. However, the interactions described above occur through other pharmacokinetic mechanisms, primarily through induction of caspofungin clearance pathways.

Unlike many azole antifungals, caspofungin does not significantly interact with most commonly used medications. However, always inform your healthcare team about all medicines you are taking. In particular, patients receiving multiple immunosuppressive agents (such as transplant recipients on both cyclosporine and tacrolimus regimens) require careful dose adjustments and enhanced monitoring.

What Is the Correct Dosage of Cancidas?

Cancidas is administered once daily by slow intravenous infusion over approximately one hour. Adults receive a 70 mg loading dose on day one, followed by 50 mg daily. Children are dosed by body surface area (70 mg/m² loading, then 50 mg/m² daily, max 70 mg). Dose reductions apply for moderate liver impairment.

Cancidas is always prepared and administered by qualified healthcare professionals in a hospital or clinical setting. It is given once daily by slow intravenous (IV) infusion over approximately one hour. The duration of treatment is determined by your doctor based on the type and severity of your infection, your clinical response, and the recovery of your immune function.

Adults

Children and Adolescents

The dose for children and adolescents aged over 3 months differs from the adult dose. In pediatric patients, the dose is calculated based on the child's body surface area (BSA), which takes into account both height and weight. The body surface area is typically calculated using the Mosteller formula.

• Loading dose (Day 1): 70 mg per square meter of body surface area (mg/m²), administered by intravenous infusion. The maximum loading dose must not exceed 70 mg regardless of the calculated value.
• Maintenance dose (Day 2 onwards): 50 mg/m² once daily by intravenous infusion. The maximum daily maintenance dose must not exceed 70 mg.

Clinical studies have shown that children often metabolize caspofungin more rapidly than adults on a per-body-weight basis, which is why dosing by body surface area is used to achieve comparable drug exposure.

Elderly

No specific dose adjustment is required for elderly patients. Clinical trials included patients aged 65 years and older, and no clinically meaningful differences in pharmacokinetics, safety, or efficacy were observed compared to younger adults. However, elderly patients should be monitored closely, as they may have reduced hepatic and renal function and are more likely to be taking multiple medications that could interact with caspofungin.

Missed Dose

Because Cancidas is administered by healthcare professionals in a clinical setting, missed doses are uncommon. If a dose is inadvertently missed, it should be given as soon as possible, and the regular daily schedule should be resumed thereafter. Do not give a double dose to make up for a missed one.

Overdose

Your doctor will determine the appropriate dose and carefully monitor your treatment. If you are concerned that you may have received too much Cancidas, speak with your doctor or nurse immediately. In clinical studies, single doses of up to 210 mg have been administered without clinically significant adverse effects. Caspofungin is not dialyzable, so hemodialysis would not be expected to remove the drug from the body.

What Are the Side Effects of Cancidas?

Common side effects of Cancidas include decreased hemoglobin, low white blood cell and potassium levels, headache, vein inflammation, shortness of breath, nausea, diarrhea, abnormal liver tests, rash, itching, fever, and chills. Serious allergic reactions and severe skin reactions (SJS/TEN) are rare but require immediate medical attention.

Like all medicines, Cancidas can cause side effects, although not everybody gets them. As with any antifungal medication, the benefits of treating a serious invasive fungal infection must be weighed against the risk of adverse reactions. Most side effects associated with caspofungin are mild to moderate in severity and are manageable with supportive care. Your healthcare team will monitor you closely during treatment.

Side Effects in Adults

Side Effects in Children and Adolescents

Reporting Side Effects

If you experience any side effects, talk to your doctor or nurse. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you can help provide more information on the safety of this medicine.

How Should You Store Cancidas?

Unopened Cancidas vials must be stored in a refrigerator at 2°C to 8°C. Once reconstituted, the solution should be used immediately as it contains no preservatives. The reconstituted concentrate may be stored for up to 24 hours at or below 25°C. The final diluted infusion solution should be used within 24 hours at room temperature or within 48 hours if refrigerated.

Proper storage of Cancidas is essential to maintain its efficacy and safety. As a hospital-administered medication, the storage and preparation of Cancidas are handled entirely by healthcare professionals. Patients do not need to store or handle this medication at home.

• Unopened vials: Store in a refrigerator at 2°C to 8°C (36°F to 46°F)
• Reconstituted concentrate: Should be used immediately. If not used promptly, it may be stored for up to 24 hours at 25°C (77°F) or below
• Diluted infusion solution: Should be used within 24 hours at 25°C or below, or within 48 hours if stored at 2°C to 8°C
• No preservatives: Because the product does not contain antimicrobial preservatives, it should be prepared aseptically and used as soon as possible after reconstitution

Keep this medicine out of the sight and reach of children. Do not use Cancidas after the expiry date stated on the carton and vial. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.

What Does Cancidas Contain?

The active substance in Cancidas is caspofungin, available as 50 mg or 70 mg vials of powder for concentrate for solution for infusion. Inactive ingredients include sucrose, mannitol (E421), glacial acetic acid, and sodium hydroxide.

Each vial of Cancidas contains a precisely measured amount of the active ingredient caspofungin in the form of a sterile, white to off-white compact powder. The medication is formulated to be reconstituted with water for injections and then further diluted before intravenous administration.

Active Ingredient

• Cancidas 50 mg: Each vial contains 50 mg of caspofungin (as caspofungin acetate)
• Cancidas 70 mg: Each vial contains 70 mg of caspofungin (as caspofungin acetate)

Excipients (Inactive Ingredients)

• Sucrose — bulking agent and stabilizer
• Mannitol (E421) — bulking agent
• Glacial acetic acid — pH adjustment
• Sodium hydroxide — pH adjustment

Appearance and Packaging

Cancidas is a sterile, white to off-white compact powder supplied in glass vials. Each package contains one vial of powder. After reconstitution with 10.5 mL of water for injections, the concentrate contains 5.2 mg/mL (50 mg vial) or 7.2 mg/mL (70 mg vial) of caspofungin. The reconstituted solution should be clear and colorless. Do not use if the solution is cloudy or contains precipitates.

Preparation Notes for Healthcare Professionals

Cancidas must not be dissolved or diluted with glucose-containing solutions, as caspofungin is not stable in such solutions. Only sodium chloride injection solution (0.9%, 0.45%, or 0.225%) or lactated Ringer's solution should be used for dilution. The drug must not be mixed or co-infused with other medications due to a lack of compatibility data. Standard infusion volume is 250 mL, though a reduced volume of 100 mL may be used when medically necessary for the 50 mg or 35 mg doses.

Available Brands and Generic Equivalents

Caspofungin is available under the original brand name Cancidas as well as several generic equivalents including Caspofungin Sandoz, Caspofungin Tillomed, Caspofungin Viatris, Caspofungin Orion, Kaspofungin Lorien, and Caspofungin STADA. All contain the same active ingredient and are therapeutically equivalent.

Following the expiration of the original patent, several pharmaceutical companies have introduced generic versions of caspofungin. These generic products contain the same active ingredient in the same dosage forms and strengths and have been approved by regulatory authorities such as the European Medicines Agency (EMA) based on demonstrated bioequivalence to the originator product. All generic versions undergo the same rigorous quality testing and manufacturing standards as the originator.

• Cancidas — the original brand manufactured by Merck Sharp & Dohme B.V.
• Caspofungin Sandoz — generic by Sandoz
• Caspofungin Tillomed — generic by Tillomed Laboratories
• Caspofungin Viatris — generic by Viatris (formerly Mylan)
• Caspofungin Orion — generic by Orion Pharma
• Kaspofungin Lorien — generic by Lorien Pharma
• Caspofungin STADA — generic by STADA Arzneimittel

Your hospital pharmacy will determine which brand of caspofungin is used based on availability and institutional formulary decisions. Regardless of the brand, the clinical efficacy and safety profile are expected to be equivalent.